S_q To test the role of serotonin in chemotherapy-induce nausea and emesis, ten cancer patets were pretreated with the seroton synthesis inhibitor para-chlorophenylalanine (PCPA) 
Cancer chemotherapeutic drugs are known to induce nausea and emesis as side-effects (Gralla, 1983; Martin 1992) . The ability of 5-HT3 receptor antagonists to inhibit chemotherapy-induced emesis (Costal et al., 1986; Miner and Sanger, 1986; Cubeddu et al., 1990 ) and the observation that emesis due to chemotherapeutic drugs is associated with the relase gastrointestinal serotonin (Cubeddu et al., 1990 Cubeddu and Hoffmann, 1994) suggests that serotonin plays a key role in mediating emesis induced by cancer chemotherapy. In ferrets, depletion of tissue serotonin reduced cisplatin and whole-body radiation-induced emesis (Bares et al., 1988; Andrews et al., 1994) . In the present study, we investigated whether pretreatment of cancer patients with para-chlorophenyLalanine (PCPA) , an inhibitor of serotonin synthesis, prevents cisplatin-induced emesis and serotonin release. The urinary excretion of 5-hydroxyindoleatic acid (5-HIAA), a marker of gastrointestinal serotonin rekase, and the development of nausea and vomiting after chemotherapy with cisplatin were evaluated in cancer patients pretreated with PCPA.
Ptts and inthod
Ten adult, chemotherapy-naive inpatients with cancer (seven head and neck and three genitourinary tumours) were studied. Written informed consent was obtained from all patients. The study was evaluated and accepted by the Institutional Review Board at the Luis Razetti Oncology Hospital of the city of Caracas.
Chemotherapy
All patients received a 60 min intravenous infusion of cisplatin (70-100 mg m-2; mean ± s.e.m. = 93 ± 3 mg m2) either alone or associated with mikily emetogenic drugs such as 5-fluorouracil or etoposide.
PCPA treatment
One subject (male) received 1 g twice daily for 2 days and 1 g prior to cisplatin. Two patients ( October 1994 received 2 g twice daily for 2 days. Four subjects (2M/2F) received 2 g three times daily for 2 days and three patients (2M/IF) received 2 g three times daily for 3 days. The last dose of PCPA (1 g in one subject and 2 g in nine subjects) was given on the morning of the day of chemotherapy, 1-2 h before initiating the infusion of cisplatin.
Antiemetic and antinusea activity of PCPA Vomiting was directly monitored by the investigators during the first 8 h following cisplatin administation. The number of emetic epiodes and the intensity of each emetic episod (number of retches and vomits per episode) were registered.
Subsequently, and for the next 16 h, the emetic episodes were recorded by the patient on a dairy. Delayed emesis was not evaluated.
Antiemetic rescue treatment was initered if patients experienced three episodes of emesis in any 1 h period. Ondansetron (8 mg i.v.) was used as rescue antiemetic. The administration of rescue antiemetic was considered to indicate insufficient efficacy of the PCPA treatment. The intensity of nausea was evaluated by means of a 100mm visual analogue scale. Nausea scores were measured the day before the chemotherapy, hourly for the first 8 h after cisplatin and at 12 and 24 h after isplatin administration.
Uriay excretion of 5-HIAA Foods known to have a high serotonin content, as well as alcohol-containing beverages, were discontinued from 2 days before initiating the urine colection until the end of the study. Twenty-four hour urine collections (spontaneous 5-HLAA excretion) were obtaied the day prior to initiation of treatment with PCPA (baselne levels), during treatment with PCPA and for 2 days after termination of the PCPA treatment (Figure 1 ). During the day of the chemotherapy, urine samples were colleted at 2 h intervals for a period of 10 h, starting 2 h before the administration of cisplatin. Subsequently, a 14 h urine sample was obtained to complete the 24 h collction period for the day of chemotherapy. 5-HIAA was determined by high-pressure liquid chromatography with electrochenical detection, as previously described (Cubeddu et al., 1990 (Figure 1 ). Cisplatin is known to increase the urinary excretion of 5-HIAA (Cubeddu et al., 1990 (Figure 2a and b). Pretreatment with 6 g daily of PCPA inhibited cisplatininduced increases in urinary 5-HIAA; 3 days' treatment with PCPA was more effective than 2 days' treatment. In fact, the amount of 5-HIAA released by cisplatin averaged 0.13 mg after 3 days and 1.44 mg after 2 days of treatment with PCPA. With lower doses of PCPA, cisplatin released 4.1 ± 0.4mg of 5-HLAA in 8 h, an amount similar to that observed previously in patients treated with similar high doses of cisplatin (3.8 ± 0.4 mg of 5-HIAA in 8 h) (Cubeddu et al., 1990, Cubeddu and Hoffmann, 1994) .
The emetic response to cisplatin-based chemotherapy is shown in Table I The antiausea efficacy of PCPA is shown in Figure 3 . Nausea scores increased at 2 h after initiation of cisplatin infusion, peaked at 3 h and rmained elevated for the 24 h obration period. Smaller nausea scores (better control of nausea) wme obtained with 6 than with 4 g daily of PCPA. Further, better control of nausea was obtained with 3 than with 2 days of treatment with PCPA (6 g daily). Interestingly, no differences were observed in the latency of onset of nausea between PCPA treatment groups despite the fact that increased latency to emesis was observed after high-dose PCPA.
No serious adverse events were observed in the study. Headache was reported by 4/10 subjects, constipation by 3/10 subjects and sadness, lack of energy and desire to stay in bed were present in three subjects.
PCPA is a well-known serotonin synthesis inhibitor, which has been previously inid to human subjects and patients (Cremata and ; Koe and Weissman, 1966; Enge}man et al., 1967) . In healthy subjects, daily PCPA doses of 2g for 12 days or 3 g for 5 days produced no serious adverse events. Tiredness, lightheadedness, diinss, loss of bala, headache and nausea were the most commonly reported side-effects. These side-effects disappeared 1-2 days after discontinuing PCPA. Further, PCPA produced no alterations in the haematological or chemical laboratory profile of the subjects (Cremata and . In patients harbouring carcinoid tumours, PCPA has been administered for prolonged periods of time (from 7 days to 5 months) at doses as high as 4 g daily and up to 28 g in 7 days and 300 g in 5 months (Engelman et al., 1967) . These authors reported no serious adverse events, and fatigue, diziness and headache were the most common side-effects observed. The goal of the present work was to achieve important serotonin depletion in a short time period, in order to avoid any delay in administering the indicated chemotherapy treatment to the cancer patients. For better monitoring, as well as for safety reasons, only inpatients were studied, a maxiimum of 3 days' treatment was given, the first three patients received the lowest doses of PCPA and all patients were closely monitored by an investigator during the period of treatment and for three additional days following treatment cessation. Similarly to what has been reported by others (see above), PCPA was well tolerated and no serious adverse events occurred. The side-effects observed by us (headaches, constipation and lack of energy) are similar-to those observed by Cremata and Koe (1966) and by Engelman et al. (1967) , and to those observed with ondansetron, a selective antagonist of 5-HT3 receptors (Cubeddu et al., 1990 (Cubeddu et al., , 1994 .
The gut is estimated to contain more than 80% of the serotonin in the body, and, of this, 95% is located within the enterochromaffin cells (Resnick and Gray, 1961) . When the gastrointestinal tract is totally or partially resected, the urinary excretion of 5-HIAA is abolished or reduced respectively (Bertaccini, 1960; Bertaccini and Chieppa, 1960) . These findings as well as other evidence indicate that urinary excretion of 5-HIAA provides a convenient index of serotonin release from the gastrointestinal tract (Cubeddu, 1992) . Cisplatin-induced serotonin release is manifested in cancer patients by increases in urinary 5-HIAA (Cubeddu et al., 1990 Cubeddu and Hoffmann, 1993) . In this work, we demonstrated in human cancer patients that treatment with a serotonin synthesis inhibitor decreases the spontaneous urinary excretion of 5-HIAA and, in addition, reduces the cisplatin-induced increases in urinary 5-HIAA. These effects of PCPA on 5-HIAA excretion are most likely the consequence of depletion of gastrointestinal serotonin. Associated with the reduction in urinary 5-HIAA, PCPA antagonised cisplatin-induced nausea and emesis, and the antiemetic activity of PCPA was similar to or even better than that previously reported by us with ondansetron, a selective antagonist of 5-HT3 receptors (Cubeddu et al., 1990) . Consequently, although based on a small number of patients, our results provide further support for the view that the emetic action of isplatin is mediated by the release of gastrointestinal serotonin induced by the chemotherapeutic drug. When the gastrointestinal serotonin content is markedly reduced (diminished spontaneous 5-HLAA excretion), cisplatin can only elicit a very small release of serotonin, associated with little or no nausea and vomiting (present study).
PCPA is known to deplete neuronal stores of serotonin more rapidly and effectively than the serotonin located in endocrine cells (enterochromaffin cells) (Weber, 1970) . For example, chronic PCPA treatment in ferrets reduced serotonin levels in the dorsal brain stem and the hypothalamus by more than 90%, whereas the levels in duodenum and ileum were reduced by 25% and 55% respectively (Andrews, 1994) . Assuming that in humans PCPA retains its greater seectivity for neuronal than for enterochromaffin serotonin, it is expected that a 50% reduction in urinary 5-HLAA should be accompanied by a marked depletion of neuronal serotonin. Consequently, the failure of low-dose PCPA to inhibit the emetic response to cisplatin despite reducing urinary 5-HIAA by 50% supports the view that it is enterochromaffin and not neuronal serotonin which mediates the emetic response to cisplatin.
In conclusion, administration of the inhibitor of serotonin synthesis, PCPA, to cancer patients reduced the spontaneous urinary excretion of 5-HIAA and inhibited the increase in urinary 5-HIAA and the nausea and vomiting induced by cisplatin. Nausea and vomiting were antagonised when the amount of serotonin released by cisplatin was considerably reduced. These findings strongly support the view that serotonin released from gastrointestinal enterochromaffin cells mediates the emetic response to cisplatin in human patients. In addition, we suggest that the amount of serotonin released is a main determinant of the severity of the emetic response to cisplatin. However, it should be stressed that serotonin release is probably one of the many effects of chemotherapy that are involved in the tnrggering of emesis.
